Increased c-kit (CD117) expression in malignant mammary phyllodes tumors

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Michael C. Heinrich, Christopher L. Corless, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 2.3K citations

Medicine, Molecular Medicine, Oncology +17

Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies

Michael C. Heinrich · Journal of Clinical Oncology · 2002 · 580 citations

Medicine, Oncology, Pharmacology +17

Mutations in Exon 11 of c-Kit Occur Preferentially in Malignant versus Benign Gastrointestinal Stromal Tumors and Do Not Occur in Leiomyomas or Leiomyosarcomas

Jerzy Lasota, Marek Jasiński, Maarit Sarlomo‐Rikala et al. · American Journal Of Pathology · 1999 · 550 citations

Medicine, Genetics, Oncology +10

Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

Jaap Verweij, A. van Oosterom, Jean‐Yves Blay et al. · European Journal of Cancer · 2003 · 403 citations

Medicine, Oncology, Gastrointestinal Oncology +12

Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues

Yukio Tsuura, Hiroyuki Hiraki, K. Watanabe et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 1994 · 207 citations

Medicine, Oncology, Pathology +17